Janssen agreed to change the brand name for galantamine products due to continued confusion with Aventis' Amaryl, which has resulted in medication errors. The company will submit new proposed names to FDA for review.

Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.